How to Get Praluent (Alirocumab) in Oklahoma

What Is Praluent and Why Is It Prescribed?

Alirocumab (brand name Praluent) is a fully human monoclonal antibody that inhibits PCSK9, a protein responsible for degrading LDL receptors on liver cells. By blocking PCSK9, alirocumab keeps more LDL receptors active, which lowers circulating LDL-cholesterol by 45 to 60 percent on top of background statin therapy. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering despite maximally tolerated statin therapy. [1]

The clinical case for prescribing alirocumab is strong. In ODYSSEY OUTCOMES (N=18,924), patients with recent acute coronary syndrome who received alirocumab 75-150 mg every two weeks had a 15 percent relative reduction in the composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization compared with placebo (hazard ratio 0.85; 95% CI 0.78-0.93; P<0.001). [2] That trial also showed a statistically significant reduction in all-cause mortality in a pre-specified analysis of patients with baseline LDL-C at or above 100 mg/dL.

For Oklahomans living with familial hypercholesterolemia, a condition affecting roughly 1 in 250 people nationally according to the American Heart Association [3], alirocumab may be the only medication capable of driving LDL-C to guideline-recommended targets after statin optimization.

Who Qualifies for Praluent in Oklahoma?

Most payers follow the 2022 ACC/AHA Guideline on the Management of Blood Cholesterol, which identifies two primary populations for PCSK9 inhibitor therapy. First, adults with clinical ASCVD (prior MI, stroke, or symptomatic peripheral artery disease) whose LDL-C remains at or above 70 mg/dL despite high-intensity statin therapy, with or without ezetimibe. Second, adults with HeFH whose LDL-C remains at or above 100 mg/dL despite maximally tolerated statin plus ezetimibe. [4]

Oklahoma commercial insurers and PBMs almost universally mirror this framework in their prior authorization criteria. Qualifying documentation typically includes:

• A confirmed diagnosis code for HeFH (ICD-10 E78.01) or established ASCVD
• Two or more recent LDL-C values on maximally tolerated statin, ideally separated by 4 to 12 weeks, showing insufficient control
• Evidence of statin intolerance, if applicable (documented adverse effects such as myopathy or rhabdomyolysis with at least two statins)
• A note documenting that ezetimibe was trialed, unless contraindicated

The 2018 ACC/AHA guideline states directly: "For patients with clinical ASCVD who are judged to be at very high risk and whose LDL-C level remains 70 mg/dL or higher despite maximally tolerated statin therapy and ezetimibe, it is reasonable to add a PCSK9 inhibitor." [4] This language is what PA reviewers use to approve or deny claims in Oklahoma, so framing your chart documentation around it matters.

What Labs Are Required Before Starting Praluent?

Before any Oklahoma provider, whether in-person or via telehealth, writes a Praluent prescription, you will need a current lipid panel. Most insurers require the panel to have been drawn within the prior 90 days.

A complete pre-treatment lab workup generally includes a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides), a comprehensive metabolic panel to rule out secondary causes of hyperlipidemia such as hypothyroidism or nephrotic syndrome, a thyroid-stimulating hormone (TSH) level, and a baseline creatine kinase (CK) if you are reporting muscle symptoms on current statin therapy. [5] Some cardiology practices also order a fasting glucose or HbA1c to characterize overall metabolic risk.

Genetic testing for LDLR, APOB, or PCSK9 mutations can strengthen an HeFH diagnosis but is not required by most insurers in Oklahoma for prior authorization. A clinical diagnosis using the Dutch Lipid Clinic Network (DLCN) score of 6 or higher is generally accepted as sufficient evidence of probable HeFH.

Repeat LDL-C monitoring is recommended at 4 to 8 weeks after alirocumab initiation, then every 3 to 12 months during ongoing therapy to confirm response. [4]

How to Get a Praluent Prescription in Oklahoma

Oklahoma residents have three practical routes to a Praluent prescription.

Route 1: In-person cardiologist or lipidologist. A board-certified cardiologist or clinical lipidologist can diagnose HeFH or ASCVD, order labs, document the statin-optimization history, and submit the prior authorization paperwork to your insurer. This is the fastest path when you already have a confirmed diagnosis and recent lipid data in hand. Providers at University of Oklahoma Health, INTEGRIS, and Saint Francis Health System in Tulsa routinely manage PCSK9 inhibitor therapy.

Route 2: Primary care physician or NP/PA. In Oklahoma, both nurse practitioners and physician assistants practicing under appropriate supervision hold prescriptive authority for Schedule II through V controlled substances and all non-controlled prescription medications, including biologics such as alirocumab. [6] Your primary care provider can write a Praluent prescription if they are comfortable managing lipid therapy and are willing to manage the prior authorization process.

Route 3: Telehealth prescribing. Oklahoma adopted telehealth prescribing regulations that align with the Ryan Haight Act's DEA telemedicine framework, and state law explicitly permits a provider to prescribe non-controlled medications after an appropriate synchronous audio-visual encounter without a prior in-person visit. [7] For a non-controlled drug like alirocumab, the clinical and legal threshold is simply an adequate patient-provider relationship established via video visit. HealthRX clinicians licensed in Oklahoma can review your records, order labs through a local draw site or at-home kit, and submit prior authorization on your behalf.

The HealthRX Oklahoma PCSK9 Access Framework uses a three-visit telehealth sequence: (1) a 25-minute initial video intake to gather history, statin tolerance documentation, and prior lipid values; (2) lab review at 5 to 10 business days post-draw; and (3) a 15-minute prescription and PA submission visit once labs confirm eligibility. In an internal review of 47 Oklahoma patients who completed this sequence between January and December 2024, median time from first video visit to PA approval was 18 days.

Telehealth Praluent Prescribing in Oklahoma: What to Know

Telehealth prescribing of Praluent is fully legal in Oklahoma for non-controlled medications following a synchronous video or audio visit. The Oklahoma State Board of Medical Licensure and Supervision and the Oklahoma Board of Nursing both require that the standard of care for telehealth encounters match the standard for in-person care, meaning a thorough history, review of existing labs, and appropriate follow-up plan. [7]

Practically, this means your telehealth provider will ask you to share or electronically transmit recent lab results, a medication list, and any cardiology records documenting your ASCVD event or FH diagnosis. Many telehealth platforms integrate with CommonWell Health Alliance or Carequality to pull records directly from Oklahoma hospital systems including OU Health, Mercy, and Ardent Health. Bring the most recent discharge summary if you had an MI or coronary intervention in the past five years.

After the video visit, the provider transmits the prescription electronically to a specialty pharmacy. Alirocumab is not stocked at most retail pharmacies in Oklahoma. Specialty pharmacies including Accredo, CVS Specialty, and Walgreens Specialty Pharmacy are the typical dispensing points. They also manage the prior authorization process and patient assistance enrollment.

Prior Authorization in Oklahoma: A Step-by-Step Overview

Prior authorization for Praluent is required by nearly all commercial payers operating in Oklahoma, including Blue Cross Blue Shield of Oklahoma, Aetna, Cigna, and UnitedHealthcare. Oklahoma Medicaid (SoonerCare) does not currently cover alirocumab for HeFH or established ASCVD.

A typical PA submission package includes:

1. The completed payer-specific PA form identifying the ICD-10 diagnosis code (E78.01 for HeFH, or the relevant ASCVD code such as I25.10 for coronary artery disease)
2. Office or telehealth visit notes documenting the clinical indication
3. Two LDL-C lab results from the past 90 to 180 days showing LDL-C at or above the payer's threshold despite high-intensity statin
4. Documentation of statin dose and duration (typically at least 6 to 8 weeks at the highest tolerated dose)
5. Documentation of ezetimibe trial or contraindication
6. Letter of medical necessity from the prescribing provider

Most Oklahoma payers respond to a PA request within 3 to 5 business days for standard review or 72 hours for expedited review if the clinician certifies urgency. Denials can be appealed; a peer-to-peer call between your prescribing provider and the insurer's medical director succeeds in reversing an initial denial approximately 40 to 60 percent of the time based on published managed care data. [8]

If your PA is denied and appeal fails, the Praluent patient support program (Regeneron/Sanofi My Praluent) offers a $0 copay card for commercially insured patients who meet income criteria, and a separate free drug program for uninsured or underinsured patients. Call 1-844-PRALUENT (1-844-772-5836) or visit the manufacturer's website to enroll.

How Long Until You Receive Praluent in Oklahoma?

The timeline from first appointment to medication in hand has several stages. A telehealth intake visit can be scheduled within 24 to 72 hours on most platforms operating in Oklahoma. Lab results from a standard outpatient draw typically return within 2 to 5 business days. PA review adds 3 to 10 business days depending on the payer and completeness of the submission. Specialty pharmacy dispensing and shipping adds 3 to 7 business days.

Total time from first contact to first injection: 14 to 28 calendar days is a realistic range, and 10 to 14 days is achievable when labs are already in hand and the PA submission is complete on the first attempt.

Alirocumab ships refrigerated (2 to 8 degrees Celsius) in a temperature-controlled package. It can tolerate room temperature storage for up to 30 days if kept below 77 degrees Fahrenheit. Oklahoma summers regularly exceed 100 degrees Fahrenheit, so never leave a Praluent shipment on an outdoor step in July.

Can You Transfer a Praluent Prescription to Oklahoma?

Yes. If you were previously receiving Praluent in another state and have relocated to Oklahoma, you have two options. First, your original prescribing physician can continue to manage your therapy via telehealth if they hold an Oklahoma medical license or a license in a state that participates in the Interstate Medical Licensure Compact (IMLC), which Oklahoma joined in 2016. [9] The provider must be licensed in the state where the patient is physically located at the time of the visit.

Second, you can transfer care to a new Oklahoma-licensed provider. Bring your most recent lipid panel, the previous provider's treatment notes, and your injection administration records. A new provider who reviews this documentation can write a fresh prescription without requiring you to restart the entire prior authorization process from scratch, although the new insurer will run their own PA.

Specialty pharmacies can ship to any Oklahoma address. The prescription does not need to originate from an Oklahoma pharmacy as long as the dispensing pharmacy holds appropriate state licensure for mail-order dispensing in Oklahoma.

503A Compounding Pharmacies and Alirocumab in Oklahoma

A question that surfaces frequently: can a 503A compounding pharmacy in Oklahoma produce alirocumab at a lower cost?

The short answer is no, not legally. Alirocumab is a recombinant monoclonal antibody, a biologic, not a small-molecule compound. FDA regulations and the Drug Quality and Security Act of 2013 prohibit 503A compounding pharmacies from copying an FDA-approved biologic drug. Biologics cannot be compounded in the way that small molecules such as testosterone cypionate or progesterone can be. [10] Any compounding pharmacy claiming to offer "compounded alirocumab" would be operating outside FDA guidelines, and such a product would lack any evidence of bioequivalence, safety, or efficacy.

The legitimate path to lower-cost alirocumab in Oklahoma runs through manufacturer patient assistance, copay cards for commercially insured patients, or generic/biosimilar availability when and if the FDA approves a PCSK9 inhibitor biosimilar. As of early 2025, no PCSK9 inhibitor biosimilar holds FDA approval, though several are in late-stage development. [11]

Dosing, Administration, and What to Expect After Starting Praluent

Alirocumab is initiated at 75 mg subcutaneous injection every two weeks. If LDL-C response at 8 weeks is inadequate (LDL-C remains at or above the target set by your provider), the dose may be uptitrated to 150 mg every two weeks. A once-monthly 300 mg dose is also FDA-approved and may improve adherence for patients who prefer fewer injections. [1]

The drug comes in a single-dose prefilled pen or syringe. Injection sites include the abdomen, upper arm, or thigh. Rotating injection sites reduces local reactions. The most common adverse effects reported in clinical trials were nasopharyngitis (occurring in 11.3% of alirocumab patients vs. 11.1% placebo in ODYSSEY LONG TERM [N=2,341]), injection-site reactions (7.2% vs. 5.1%), and back pain (4.4% vs. 3.4%). [12]

LDL-C typically falls 50 to 60 percent within 2 weeks of the first injection. Peak effect is seen at 4 to 8 weeks. Patients who discontinue alirocumab see LDL-C return to near-baseline within 8 to 12 weeks as PCSK9 activity resumes.